Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Entera Bio Ltd.NASDAQ: ENTX
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI broadly unchanged from a year ago
Accumulated OCI stood at $41K at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Accumulated OCI amounted to 0.3% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Accumulated OCI increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 41K USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +0.0%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41K | +0.0% |
| FY2024 | 2024-12-31 | 41K | +0.0% |
| FY2023 | 2023-12-31 | 41K | +0.0% |
| FY2022 | 2022-12-31 | 41K | +0.0% |
| FY2021 | 2021-12-31 | 41K | — |
Accumulated OCI vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 Accumulated OCI of $41K is the highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +0.0% is the 5th highest of 6, against a peer median of +40.0%.
- Accumulated OCI amounts to 0.3% of total assets for ENTX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $41K | +0.0% | +0.0% | 0.3% | |
| Mar 2026 | $21K | +40.0% | — | 0.0% | |
IRDOpus Genetics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Apr 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$64K | -121.0% | — | 0.0% | |
| Mar 2026 | -$437K | +70.2% | — | 0.2% | |
| Mar 2026 | -$636.09K | +3.8% | — | 1.3% | |
| Peer median (excluding ENTX) | $0 | +40.0% | — | 0.0% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.